REDX PHARMA PLC
("Redx" or the "Company")
Result of General Meeting and Cancellation of Admission to Trading on AIM
Alderley Park, UK, 19 April 2024 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, targeted therapeutics for the treatment of fibrotic disease and cancer announces that, at the general meeting of the Company held earlier today (the "General Meeting"), all resolutions put to the Company's shareholders ("Shareholders") were duly passed on a poll.
The table below sets out the details of the votes put to Shareholders:
| Resolution Number (*indicates special resolution) | Resolution Name | Votes For | Votes Against | Votes Withheld* | Total Votes Cast (excl. withheld) | ||
| No. of shares | % of shares voted | No. of shares | % of shares voted | No. of shares | |||
| 1* | Cancellation Resolution | 351,522,100 | 99.75% | 882,304 | 0.25% | 4,291 | 352,404,404 |
| 2* | Re-registration Resolution and Adoption of New Articles of Association | 351,522,100 | 99.75% | 882,304 | 0.25% | 4,291 | 352,404,404 |
*A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes 'For' or 'Against'
The full text of the resolutions proposed and passed at the General Meeting can be found in the circular containing, inter alia, the Notice of General Meeting, which was published and posted to Shareholders on 2 April 2024 and is available on the Company's website www.redxpharma.com (the "Circular").
AIM Delisting
Following approval by Shareholders at the General Meeting, the admission of the ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") to trading on AIM will be cancelled (the "AIM Delisting"). The AIM Delisting is expected to take place at 7:00 a.m. on 1 May 2024 and, accordingly, the last day of dealings in Ordinary Shares on AIM is expected to be 30 April 2024.
Matched Bargain Facility
It remains the Company's intention to provide a matched bargain facility to assist Shareholders wishing to trade in Ordinary Shares following the AIM Delisting. Further details with respect to the matched bargain facility, to be provided by J P Jenkins, will be made available in due course on the Company's website www.redxpharma.com.
Capitalised terms used but not defined in this announcement shall have the same meaning given to such terms in the Circular.
| For further information, please contact: | | |
| |
| Redx Pharma Plc UK Headquarters Caitlin Pearson, Head of Communications
| T: +44 (0)1625 469 918 | |||
| SPARK Advisory Partners (Nominated Adviser) | T: +44 (0)203 368 3550 | |||
| Matt Davis/Adam Dawes | | |||
| | | |||
| Panmure Gordon (UK) Limited (Broker) | T: +44 (0)207 886 2500 | |||
| Rupert Dearden/Freddy Crossley/Emma Earl | | |||
| | | |||
| FTI Consulting | T: +44 (0)203 727 1000 | |||
| Simon Conway/Ciara Martin | | |||
About Redx Pharma Plc
Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted therapeutics for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis. Redx aims to progress its programmes to clinical proof of concept before evaluating options for further development and potential value creation. The Company expects a number of data points during 2024 including from lead fibrosis product candidate, the selective ROCK2 inhibitor, zelasudil (RXC007), in development for interstitial lung disease and currently undertaking a Phase 2a trial for idiopathic pulmonary fibrosis (IPF). The Company's second fibrosis candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, is in Phase 1 development and is expected to report healthy volunteer data; and Redx's lead oncology product candidate, the Porcupine inhibitor zamaporvint (RXC004), being developed as a targeted treatment for Wnt-ligand dependent cancers, is expected to report anti-PD-1 combination Phase 2 data, following which Redx will seek a partner for ongoing development.
The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its wholly-owned clinical-stage product candidates and discovery pipeline, but also by its strategic transactions, which includes the sale of pirtobrutinib (RXC005, LOXO-305), the only non-covalent or reversible BTK inhibitor now approved by the US FDA, and transactions with both AstraZeneca and Jazz Pharmaceuticals.
To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.